225 related articles for article (PubMed ID: 18196976)
1. NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts.
Selvendiran K; Bratasz A; Tong L; Ignarro LJ; Kuppusamy P
Cell Cycle; 2008 Jan; 7(1):81-8. PubMed ID: 18196976
[TBL] [Abstract][Full Text] [Related]
2. NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols.
Bratasz A; Selvendiran K; Wasowicz T; Bobko A; Khramtsov VV; Ignarro LJ; Kuppusamy P
J Transl Med; 2008 Feb; 6():9. PubMed ID: 18302761
[TBL] [Abstract][Full Text] [Related]
3. HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition.
Selvendiran K; Ahmed S; Dayton A; Kuppusamy ML; Rivera BK; Kálai T; Hideg K; Kuppusamy P
Cancer Biol Ther; 2011 Nov; 12(9):837-45. PubMed ID: 21885917
[TBL] [Abstract][Full Text] [Related]
4. Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells.
Yue P; Zhang X; Paladino D; Sengupta B; Ahmad S; Holloway RW; Ingersoll SB; Turkson J
Oncogene; 2012 May; 31(18):2309-22. PubMed ID: 21909139
[TBL] [Abstract][Full Text] [Related]
5. Reversal to cisplatin sensitivity in recurrent human ovarian cancer cells by NCX-4016, a nitro derivative of aspirin.
Bratasz A; Weir NM; Parinandi NL; Zweier JL; Sridhar R; Ignarro LJ; Kuppusamy P
Proc Natl Acad Sci U S A; 2006 Mar; 103(10):3914-9. PubMed ID: 16497833
[TBL] [Abstract][Full Text] [Related]
6. The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1.
Yuan Z; Cao K; Lin C; Li L; Liu HY; Zhao XY; Liu L; Deng HX; Li J; Nie CL; Wei YQ
Mol Med; 2011; 17(11-12):1262-74. PubMed ID: 21863213
[TBL] [Abstract][Full Text] [Related]
7. Abrogation of constitutive Stat3 activity circumvents cisplatin resistant ovarian cancer.
Ji T; Gong D; Han Z; Wei X; Yan Y; Ye F; Ding W; Wang J; Xia X; Li F; Hu W; Lu Y; Wang S; Zhou J; Ma D; Gao Q
Cancer Lett; 2013 Dec; 341(2):231-9. PubMed ID: 23962558
[TBL] [Abstract][Full Text] [Related]
8. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
[TBL] [Abstract][Full Text] [Related]
9. [Effects of Zengmian Yiliu Recipe combined cisplatin on the tumor inhibition rate in platinum-resistant ovarian cancer].
Qi C; Zhang QH; Li JX
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Jun; 32(6):817-21. PubMed ID: 22978111
[TBL] [Abstract][Full Text] [Related]
10. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
[TBL] [Abstract][Full Text] [Related]
11. Bcl-2 overexpression reduces cisplatin cytotoxicity by decreasing ER-mitochondrial Ca2+ signaling in SKOV3 cells.
Xu L; Xie Q; Qi L; Wang C; Xu N; Liu W; Yu Y; Li S; Xu Y
Oncol Rep; 2018 Mar; 39(3):985-992. PubMed ID: 29286126
[TBL] [Abstract][Full Text] [Related]
12. A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer.
Han Z; Hong Z; Gao Q; Chen C; Hao Z; Ji T; Hu W; Yan Y; Feng J; Liao S; Wu P; Wang D; Wang S; Zhou J; Ma D
Hum Gene Ther; 2012 Jan; 23(1):32-45. PubMed ID: 21875334
[TBL] [Abstract][Full Text] [Related]
13. Silencing of the STAT3 signaling pathway reverses the inherent and induced chemoresistance of human ovarian cancer cells.
Han Z; Feng J; Hong Z; Chen L; Li W; Liao S; Wang X; Ji T; Wang S; Ma D; Chen G; Gao Q
Biochem Biophys Res Commun; 2013 May; 435(2):188-94. PubMed ID: 23665025
[TBL] [Abstract][Full Text] [Related]
14. ABT737 reverses cisplatin resistance by regulating ER-mitochondria Ca2+ signal transduction in human ovarian cancer cells.
Xie Q; Su J; Jiao B; Shen L; Ma L; Qu X; Yu C; Jiang X; Xu Y; Sun L
Int J Oncol; 2016 Dec; 49(6):2507-2519. PubMed ID: 27748803
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
[TBL] [Abstract][Full Text] [Related]
16. ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts.
Washington MN; Suh G; Orozco AF; Sutton MN; Yang H; Wang Y; Mao W; Millward S; Ornelas A; Atkinson N; Liao W; Bast RC; Lu Z
Cell Death Dis; 2015 Aug; 6(8):e1836. PubMed ID: 26247722
[TBL] [Abstract][Full Text] [Related]
17. NOXA-induced alterations in the Bax/Smac axis enhance sensitivity of ovarian cancer cells to cisplatin.
Lin C; Zhao XY; Li L; Liu HY; Cao K; Wan Y; Liu XY; Nie CL; Liu L; Tong AP; Deng HX; Li J; Yuan Z; Wei YQ
PLoS One; 2012; 7(5):e36722. PubMed ID: 22590594
[TBL] [Abstract][Full Text] [Related]
18. The involvement of Bcl-2 family proteins in AKT-regulated cell survival in cisplatin resistant epithelial ovarian cancer.
Dai Y; Jin S; Li X; Wang D
Oncotarget; 2017 Jan; 8(1):1354-1368. PubMed ID: 27935869
[TBL] [Abstract][Full Text] [Related]
19. IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells.
Zhu X; Shen H; Yin X; Long L; Chen X; Feng F; Liu Y; Zhao P; Xu Y; Li M; Xu W; Li Y
Oncotarget; 2017 Jun; 8(24):39154-39166. PubMed ID: 28388577
[TBL] [Abstract][Full Text] [Related]
20. TRIAP1 Inhibition Activates the Cytochrome c/Apaf-1/Caspase-9 Signaling Pathway to Enhance Human Ovarian Cancer Sensitivity to Cisplatin.
Zhang TM
Chemotherapy; 2019; 64(3):119-128. PubMed ID: 31661694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
